VEGFA and Miyoshi myopathy: Bevacizumab, a monoclonal antibody directed against VEGF-A, inhibits VEGF and it has been used in the clinical practice against several types of solid malignancies [61], and also antiangiogenic therapy was tested in MM, although the results with this strategy have been disappointing [62].